Screener
Novavax NVAX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $56.7M-76.3% | $139.51M-79.1% | $147.14M+66.6% | $70.45M-16.6% | $239.24M-42.4% | ||
| $14.25M-7.0% | $30.7M+117% | $22.1M-39.7% | $21.5M-64.5% | $15.33M-66.9% | ||
| $42.45M-81.0% | $108.82M-83.3% | $125.04M+142% | $48.95M+105% | $223.92M-39.4% | ||
| 74.9%-18.7pp | 78%-19.9pp | 85%+26.5pp | 69.5%+41.2pp | 93.6%+4.7pp | ||
| $70.69M-10.8% | $95.47M+7.3% | $75.88M-27.3% | $98.27M+12.7% | $79.23M-25.9% | ||
| $26.67M-38.9% | $28.78M-40.2% | $34.12M-56.4% | $31.66M-55.3% | $43.61M— | ||
| $111.6M-19.2% | $154.94M+2.5% | $132.91M-39.4% | $248.46M+13.7% | $138.17M-45.7% | ||
| -$54.91M-154% | -$15.43M-103% | $14.23M+111% | -$178.02M-32.8% | $101.07M-37.2% | ||
| -96.8%-139pp | -11.1%-88.4pp | 9.7%+158pp | -252.7%-94.1pp | 42.2%+3.5pp | ||
| $5.69M+3.1% | $4.9M-14.4% | $5.82M-23.2% | $5.48M+29.4% | $5.52M+33.2% | ||
| $8.92M-25.1% | $11.83M+17.6% | $9.5M-27.7% | $9.18M-42.4% | $11.9M+54.0% | ||
| -$51.68M-148% | -$8.51M-102% | $17.9M+124% | -$203.04M-66.0% | $107.45M-34.7% | ||
| $1.71M+80.9% | $985K-17.9% | $376K-95.0% | -$657K+36.3% | $946K-57.1% | ||
| -$53.39M-150% | -$9.49M-102% | $17.53M+122% | -$202.38M-66.8% | $106.51M-34.4% | ||
| -94.2%-139pp | -6.8%-84.6pp | 11.9%+104pp | -287.3%-144pp | 44.5%+5.4pp | ||
| -$0.32-152% | -$0.06-102% | $0.05+110% | -$1.25-64.5% | $0.62-37.4% | ||
| -$51.85M-148% | -$12.37M-102% | $19.36M+116% | -$171.43M-41.3% | $108.63M-36.9% | ||
| -91.4%-137pp | -8.9%-87.4pp | 13.2%+147pp | -243.4%-99.8pp | 45.4%+4.0pp | ||
| -$54.91M-154% | -$15.43M-103% | $14.23M+111% | -$178.02M-32.8% | $101.07M-37.2% |
FAQ
- What is Novavax's revenue?
- Novavax (NVAX) generated $413.8M in revenue over the trailing twelve months, down 61.6% year over year.
- Is Novavax profitable?
- Novavax is not currently profitable: it reported a net loss of $247.7M over the trailing twelve months, a -59.9% net margin.
- What are Novavax's profit margins?
- Gross margin is 78.6% and operating margin is -56.6%, with a -59.9% net margin.
- What is Novavax's earnings per share?
- Novavax's diluted EPS over the trailing twelve months is $-1.58.
- Where does Novavax's income statement data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
